Crelosidenib

DB21642InvestigationalSmall molecule

Crelosidenib is a small molecule drug. Crelosidenib is under investigation in clinical trial NCT04603001 (Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations). Crelosidenib... Crelosidenib has a monoisotopic molecular weight of 504.28 Da.

Mechanism: Pharmacologically active on Isocitrate dehydrogenase [NADP] cytoplasmic and Isocitrate dehydrogenase [NADP], mitochondrial
Curator reviewed
Formula / weight: C₂₈H₃₆N₆O₃ · 504.635 g/mol (avg)
Code names: LSN-3856920 · LY-3410738

Resolves to

Compound

UNIIA4DU555RMDCAS2230263-60-0ChEMBLCHEMBL6000618ChEBI759876PubChem135125140

Structure

InChIKeyAFGYODUJVVOZAX-CYFREDJKSA-NSMILESCCN1C(=O)OCC2=C1N=C(N[C@@H](C)C1=CC=C(C=C1)[C@H](CC1CC1)N1CCN(CC1)C(=O)C=C)N=C2

Targets

O75874IDH1P48735IDH2

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Crelosidenib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account